{"id":294,"date":"2024-11-04T00:00:00","date_gmt":"2024-11-04T00:00:00","guid":{"rendered":"https:\/\/hortonspharmacy.co.uk\/promotions\/novartis-and-apellis-are-competing-to-get-their-treatments-approved-for-a-rare-kidney-disease-they-have-both-released-new-data-related-to-their-drugs-as-part-of-this-race\/"},"modified":"2025-02-27T15:55:37","modified_gmt":"2025-02-27T15:55:37","slug":"novartis-and-apellis-are-competing-to-get-their-treatments-approved-for-a-rare-kidney-disease-they-have-both-released-new-data-related-to-their-drugs-as-part-of-this-race","status":"publish","type":"post","link":"https:\/\/hortonspharmacy.co.uk\/promotions\/novartis-and-apellis-are-competing-to-get-their-treatments-approved-for-a-rare-kidney-disease-they-have-both-released-new-data-related-to-their-drugs-as-part-of-this-race\/","title":{"rendered":"Novartis and Apellis are competing to get their treatments approved for a rare kidney disease. They have both released new data related to their drugs as part of this race."},"content":{"rendered":"

Novartis and Apellis Pharmaceuticals are competing to develop treatments for a rare kidney<\/a> disease. Both companies recently shared promising results from their research on new drugs.<\/p>\n

Apellis presented detailed results from a late-stage trial of their drug, pegcetacoplan, which is aimed at treating kidney diseases called C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The drug showed success in reducing protein in the urine, a key indicator of kidney disease, by over 68% within 24 weeks. It also helped stabilize kidney function and reduced disease markers in patients.<\/p>\n

Pegcetacoplan is already approved for other conditions under the names Empaveli and Syfovre. Apellis plans to seek U.S. approval for this new use in early 2025.<\/p>\n

Novartis also reported positive results for their drug, iptacopan, marketed as Fabhalta. It showed significant reductions in urine protein levels over a year and improved kidney function in patients with C3G. Novartis has already submitted applications for approval in Europe, China, and Japan and plans to file in the U.S. soon.<\/p>\n

Both drugs were generally safe in the trials. Currently, there are no treatments targeting the root causes of C3G and IC-MPGN, which often lead to kidney failure. Apellis estimates these diseases affect about 5,000 people in the U.S. and up to 8,000 in Europe.<\/p>\n

Experts believe pegcetacoplan has strong potential to dominate the market due to its effectiveness, making it a potential blockbuster in the treatment of these rare kidney diseases.<\/p>\n","protected":false},"excerpt":{"rendered":"

Novartis and Apellis Pharmaceuticals are competing to develop treatments for a rare kidney disease. Both companies recently shared promising results […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[306],"tags":[],"class_list":["post-294","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/hortonspharmacy.co.uk\/promotions\/wp-json\/wp\/v2\/posts\/294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hortonspharmacy.co.uk\/promotions\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hortonspharmacy.co.uk\/promotions\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hortonspharmacy.co.uk\/promotions\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hortonspharmacy.co.uk\/promotions\/wp-json\/wp\/v2\/comments?post=294"}],"version-history":[{"count":1,"href":"https:\/\/hortonspharmacy.co.uk\/promotions\/wp-json\/wp\/v2\/posts\/294\/revisions"}],"predecessor-version":[{"id":395,"href":"https:\/\/hortonspharmacy.co.uk\/promotions\/wp-json\/wp\/v2\/posts\/294\/revisions\/395"}],"wp:attachment":[{"href":"https:\/\/hortonspharmacy.co.uk\/promotions\/wp-json\/wp\/v2\/media?parent=294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hortonspharmacy.co.uk\/promotions\/wp-json\/wp\/v2\/categories?post=294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hortonspharmacy.co.uk\/promotions\/wp-json\/wp\/v2\/tags?post=294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}